Morphogen-IX Announces MGX292 as Treatment Candidate for PAH
Biotechnology company Morphogen-IX recently announced that it will be further developing MGX292 as its treatment candidate for pulmonary arterial hypertension (PAH). The company’s decision is supported by previous preclinical studies that have shown the potential of MGX292, a signaling protein analogue, as a safe and effective therapy for PAH.